文献速递泌尿生殖MRUS

3D Navigo系统MRI-TRUS融合靶向前列腺穿刺活检的前瞻性研究

Prostate cancer detection by targeted prostate biopsy using the 3D Navigo system: a prospective study.
PubMed 文献 · Abdom Radiol (NY) · 2021-04-15

该前瞻性研究纳入304例接受3D Navigo系统MRI-TRUS融合靶向穿刺的患者,评估临床显著前列腺癌(CSC,ISUP≥2)检出率。结果CSC检出率为47.7%,PI-RADS评分≥4和5与CSC风险显著相关(OR分别为5.0和3.2),PI-RADS是CSC的独立危险因素。靶向穿刺与根治性前列腺切除标本的ISUP评分正相关(r=0.60)。

要点

  • PI-RADS≥4与CSC风险独立相关,阅片时应准确分级以指导靶向穿刺。
  • 靶向穿刺CSC检出率47.7%,与根治标本病理评分正相关(r=0.60)。
  • 3D Navigo系统MRI-TRUS融合靶向穿刺可行且安全,可用于前列腺癌检测。

核心结论

  • 使用3D Navigo系统进行MRI-TRUS融合靶向穿刺检测临床显著前列腺癌是可行且安全的,靶向穿刺与根治性前列腺切除标本的ISUP评分呈正相关。

研究设计与样本

  • 前瞻性单中心研究,纳入2014年6月至2018年5月在本中心接受3D Navigo系统靶向穿刺的患者,排除既往接受前列腺癌治疗者,共304例。
  • 穿刺前均行3-Tesla MRI,并按PI-RADS第2版报告结果;临床显著前列腺癌定义为ISUP评分≥2。

诊断标准与关键数值

  • 临床显著前列腺癌(CSC)定义为ISUP评分≥2。
  • PI-RADS评分≥4和5与CSC风险显著相关,OR分别为5.0(95%CI 2.7-9.2,P<0.001)和3.2(95%CI 1.8-5.5,P<0.001)。
  • PI-RADS评分是CSC的独立危险因素,OR为4.19(95%CI 2.49-7.05,P<0.001)。

临床应用与阅片要点

  • 阅片时应按PI-RADS v2准确评分,PI-RADS≥4提示CSC风险增高,应建议靶向穿刺。
  • 靶向穿刺病理ISUP评分与根治标本相关,可用于术前风险分层。

局限性

  • 单中心前瞻性研究,样本量304例,结果需多中心验证。
  • 原文未报告靶向穿刺的敏感度、特异度及AUC等诊断效能指标。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: The 3D Navigo™ system is a magnetic resonance imaging (MRI) and transrectal ultrasound (TRUS) fusion device for prostate targeted biopsies (TB). Our aim was to evaluate the clinically significant prostate cancer (CSC) detection rate of TB using the 3D Navigo™ system.

METHODS: Patients who underwent TB with the 3D Navigo™ system in our center between June 2014 and May 2018 were prospectively included, excluding those who have previously received treatment for prostate cancer. A 3-Tesla MRI imaging was performed before biopsies; findings were reported according to the Prostate Imaging Reporting and Data System version 2 (PIRADS). CSC was defined by an ISUP score ≥ 2.

RESULTS: 304 patients underwent TB. Median age was 66 years (51-84). Median PSA was 7.75 ng/ml (0.6-70.0). Median prostate volume was 45.0 ml (15.9-221.7). PCa and CSC were found in 70.4% (214/304) and 47.7% (145/304) of the patients, respectively. The proportion of patients diagnosed with CSC among those with PCa was 67.8% (145/214). There was a significant risk of having a CSC in case of PIRADS score ≥ 4 and 5 (OR 5.0, 95% CI [2.7-9.2], P < 0.001; OR 3.2, 95% CI [1.8-5.5], P < 0.001). PIRADS score was an independent risk factor of having a CSC (OR 4.19, 95% CI [2.49-7.05], P < 0.001). There was no significant difference between pathological outcomes of TB and RP in paired analysis (P = 0.892). There was a correlation between TB and RP specimens for PCa detection (r = 0.60, P < 0.001).

CONCLUSION: Detecting CSC with MRI-TRUS fusion targeted biopsies using the 3D Navigo™ system is feasible and safe. We found a positive correlation between TB and RP for ISUP scores.

来源:Abdom Radiol (NY),查看原文。版权归原作者所有。

引用

  1. Magnier A, Nedelcu C, Chelly S, et al. Prostate cancer detection by targeted prostate biopsy using the 3D Navigo system: a prospective study. Abdom Radiol (NY). 2021. PMID: 33856508. doi:10.1007/s00261-021-03078-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。